PHARMACEUTICAL COMPOSITIONS COMPRISING RANPIRNASE
This disclosure is directed to new pharmaceutical compositions comprising ranpimase and a polyol, said compositions comprise increased stability. Further disclosed are methods for treating a viral disease by administering said compositions.
1 . A pharmaceutical composition comprising ranpirnase and a polyol.
2 . The composition of claim 1 , wherein said polyol is selected from a group comprising hexylene glycol, propylene glycol, glycerol, glycerol monolaureate, and ethylene glycol, or any combination thereof.
3 . The composition of claim 1 , wherein said polyol comprises about 10% of the weight of said pharmaceutical composition.
4 . The composition of claim 2 , wherein said glycerol comprises about 5%, and said propylene glycol comprises about 5% of the weight of said pharmaceutical composition.
5 . The composition of claim 2 , wherein said glycerol comprises about 5%, and said hexylene glycol comprises about 5% of the weight of said pharmaceutical composition.
6 . The composition of claim 1 , wherein said composition is stable at room temperature.
7 . The composition of claim 6 , wherein said composition has increased stability compared to a composition comprising ranpirnase and about 10% glycerol of the weight of said pharmaceutical composition.
8 . The composition of claim 1 , wherein said composition is formulated as a gel or as a cream.
9 . The composition of claim 1 , wherein said ranpirnase is at a concentration of about 0.1% w/w.
10 . The composition of claim 1 , wherein said composition is formulated for topical or dermal application.
11 . The pharmaceutical composition of claim 1 , further comprising an antimicrobial agent.
12 . The pharmaceutical composition of claim 11 , wherein said antimicrobial agent is selected from the group comprising methylparaben, propylparaben, EDTA, or any combination thereof.
13 . The pharmaceutical composition of claim 1 , wherein said composition does not comprise an antioxidant agent.
14 . The pharmaceutical composition of claim 1 , wherein said composition comprises a pH in the range of 6.5 to 7.
15 . The pharmaceutical composition of claim 1 , further comprising a surfactant agent.
16 . (canceled)
17 . The pharmaceutical composition of claim 1 , further comprising hydroxyethyl cellulose (HEC).
18 . (canceled)
19 . A gel pharmaceutical composition comprising ranpirnase, glycerin, propylene glycol, hydroxyethyl cellulose, sodium citrate dihydrate, 10% hydrochloric acid, methylparaben, edetic acid, propylparaben and purified water, or comprising ranpirnase, hydroxyethylcellulose, EDTA, methylparaben, propylparaben, glycerol, and:
(a) propylene glycol, and/or
(b) hexylene glycol.
20 . (canceled)
21 . A cream pharmaceutical composition comprising ranpirnase, sucrose stearate, sodium dodecyl sulfate, cetostearyl alcohol, EDTA, and:
(a) light mineral oil, and/or
(b) octyldodecanol.
22 . A method for treating a viral disease in a subject in need thereof, the method comprising administering the pharmaceutical composition of claim 1 .
23 . The method of claim 22 , wherein said viral disease is selected from the group comprising a viral skin disease; herpes zoster; chickenpox; molluscum contagiosum; warts; measles; hand, foot and mouth disease, human papillomavirus (HPV) infection, or any combination thereof.